Table 2.

Discovery and validation group broken down by sex.

	Discovery group		Validation group
	Males (n = 49)	Females (n = 47)	Males (n = 100)	Females (n = 66)
Age (years ± s.d.)	49.4 ± 8.64	49.7 ± 8.29	42.9 ± 11.4	45.7 ± 13.1
Caucasian (%)/African-American (%)	55/40	65/30	53/36	53/25
Metabolic syndrome (%)	50	51	44	51
% currently smoking	57	43	55	56
Olanzapine/clozapine (%)	25	24	31	26
Quetiapine/paliperidone/risperidone (%)	35	38	44	31
Aripiprazole/ziprasidone (%)	40	38	25	43

The table depicts the mean ± s.d. or % values for the discovery and validation groups. No statistically significant differences were noted between males and females for either group. There was a trend for decreased smoking in females in the discovery group (p = 0.1).